Respiratory distress – this could present in the form of stridor, use or reliance on accessory muscles of respiratory, nasal flaring, or wheeze. These signs may develop if glandular swelling is significant enough, resulting in airway obstruction. 3. Cranial nerve palsy – swelling increases the risk of compression of cranial nerves VII, IX and XII. Other diagnostic factors which are less common
1. Connective tissue disorder or Sjogren’s syndrome – history of Sjogren’s syndrome, or a concomitant connect tissue disorder such as systemic lupus erythematosus, rheumatoid arthritis, or scleroderma. 2. Recurrent painless swellings – indicative of underlying autoimmune aetiology. 3. Displacement of earlobe – may be present when swelling of the parotid gland is present. 4. Prodrome of tingling in the affected gland
5. Swelling on hard palate

Diagnostic tests
Tests available as part of diagnosing sialadenitis include:

Culture and sensitivity testing of exudate from salivary duct. Culturing of purulent discharge is advisable in acute presentations of sialadenitis to allow targeted antibiotic therapy. Full blood count if infection is suspected. Facial radiographs such as dental radiographic views should be taken to exclude an obstructive element due to presence of sialolith or evolving abscess. However, sialoliths with low calcium phosphate content may not be visible. Treatment
In chronic recurrent sialadenitis or chronic sclerosing sialadenitis, acute attacks are managed with conservative therapies such as hydration, analgesics (mainly NSAIDs), sialogogues to stimulate salivary secretion, and regular, gentle gland massage. If infection is present, appropriate cultures should be obtained, followed by empirical antibiotic therapy initially, for example amoxicillin/clavulanate or clindamycin which cover oral flora.
Triclabendazole, sold under the brand name Egaten among others, is a medication used to treat fascioliasis and paragonimiasis. It is very effective for both conditions. Treatment in hospital may be required. It is taken by mouth with typically one or two doses being required.Side effects are generally few, but can include abdominal pain and headaches. Biliary colic may occur due to dying worms. While no harm has been found with use during pregnancy, triclabendazole has not been studied well in this population. It is a member of the benzimidazole family of medications for worms.Triclabendazole was approved for medical use in the United States in 2019. It is on the World Health Organizations List of Essential Medicines. For human use, it can be obtained from the World Health Organization. It is also used in animals. Chemistry
It is a member of the benzimidazole family of anthelmintics. The benzimidazole drugs share a common molecular structure, triclabendazole being the exception in having a chlorinated benzene ring but no carbamate group. Benzimidazoles such as triclabendazole are generally accepted to bind to beta-tubulin therefore preventing the polymerization of microtubules. History
Since late 1990s, triclabendazole became available as a generic drug, as patents expired in many countries. Many products were developed then. Among them, Trivantel 15,  a 15% triclabendazole suspension, was launched by Agrovet Market Animal Health in the early 2000s. In 2009, the first triclabendazole injectable solution (combined with ivermectin) was developed and launched, also by Agrovet Market Animal Health.